The FDA alignment on a smaller, adequately powered trial reduces execution risk and accelerates the path to a potential label expansion for mavorixafor. Traders should watch for enrollment completion by year-end 2026 and topline data in H1 2028 as key catalysts. The stock may re-rate on reduced trial risk, but the long timeline to data means near-term volatility is likely limited.
Price Chart
Executive Summary
X4 Pharmaceuticals announced a positive FDA Type C meeting outcome for its 4WARD Phase 3 chronic neutropenia trial. The FDA agreed to reduce the trial's sample size from 176 to 126 participants while maintaining adequate statistical power, and accepted the proposed safety database to support a potential sNDA. This de-risks the trial's path to completion and regulatory submission, with enrollment expected by year-end 2026 and topline data in H1 2028.
Key Facts
- FDA agreed to reduce 4WARD trial sample size from 176 to 126 participants while maintaining adequate power for co-primary endpoints.
- FDA indicated the proposed safety database is acceptable to support a potential sNDA for mavorixafor in chronic neutropenia.
- Company expects to complete enrollment by year-end 2026 and report topline data in H1 2028.
- Mavorixafor is already commercially available in the U.S. as XOLREMDI for its first indication.
- Estimated 15,000 patients with serious/recurring infections due to chronic neutropenia represent the target market.
Financial Impact
No financial figures provided in the filing. The reduced trial size (126 vs 176 patients) likely lowers trial costs and accelerates timeline to potential sNDA submission, but no dollar amounts were disclosed.
Risk Factors
- FDA feedback from Type C meetings is non-binding; the FDA may take a different position during sNDA review.
- Reduced sample size may still fail to demonstrate statistically significant results on co-primary endpoints.
- Enrollment may not complete within the expected timeframe.
- Mavorixafor may not ultimately achieve commercial success in chronic neutropenia even if approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001501697-26-000072 |
| Document: a991_x4typecoutcome.htm | 0001501697-26-000072 |
| Document: 0001501697-26-000072-index-headers.html | 0001501697-26-000072 |
| Document: 0001501697-26-000072-index.html | 0001501697-26-000072 |
| Document: 0001501697-26-000072.txt | 0001501697-26-000072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.91 | awaiting T+20 | — | $3.24 (+11.34%) |
Oct 7, 2026 19d ago | SC 13G/A | $2.81 | awaiting T+20 | — | $3.24 (+15.30%) |
Oct 1, 2026 25d ago | 144 | $2.83 | awaiting T+20 | — | $3.24 (+14.49%) |
Sep 21, 2026 5w ago | SC 13G | $3.43 $3.02 | ▼ −11.95% | ▼ −11.39% | $3.24 (−5.54%) |
Sep 8, 2026 6w ago | 8-K | $3.51 $2.77 | ▼ −20.97% | ▼ −22.68% | $3.24 (−7.56%) |
Aug 13, 2026 10w ago | Insider Cluster | $4.22 $3.62 | ▼ −14.22% | ▼ −12.23% | $3.24 (−23.22%) |
Aug 13, 2026 10w ago | 144 | $4.29 $3.50 | ▼ −18.41% | ▼ −16.67% | $3.24 (−24.48%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.24 (−16.49%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.24 (−16.49%) |
May 18, 2026 23w ago | EFFECT | $3.68 $4.04 | ▲ +9.78% | ▲ +8.20% | $3.24 (−11.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers